{"id":1170,"date":"2013-10-10T19:16:34","date_gmt":"2013-10-10T19:16:34","guid":{"rendered":"http:\/\/jacobimed.org\/NS\/?page_id=1170"},"modified":"2013-10-10T19:16:34","modified_gmt":"2013-10-10T19:16:34","slug":"smoking-tables","status":"publish","type":"page","link":"https:\/\/jacobimed.org\/old\/ambulatory\/mlove\/curriculumprevention\/smoking-cessation\/articles\/smoking-tables\/","title":{"rendered":"Smoking tables"},"content":{"rendered":"

<\/a><\/p>\n\n\n <\/map>\n

\"wjm\"<\/a> \"Sign<\/a><\/p>\n\n\n\n
HOME<\/span><\/a><\/td>\nHELP<\/span><\/a><\/td>\nFEEDBACK<\/span><\/a><\/td>\nSUBSCRIPTIONS<\/span><\/a><\/td>\nARCHIVE<\/span><\/a><\/td>\nSEARCH<\/span><\/a><\/td>\nTABLE OF
\nCONTENTS<\/span><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

<\/p>\n

 <\/p>\n\n\n\n
<\/p>\n<\/p>\n\n\n\n\n
\"\" Full Text of
\nthis Article<\/a> <\/span><\/td>\n<\/tr>\n
\"\" Email
\nthis article to a friend<\/a> <\/span><\/td>\n<\/tr>\n
\"\"
\neLetters: Submit a
\nresponse<\/a> to this article<\/strong>
\n<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/tr>\n

<\/tbody>\n<\/table>\n

<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Table 1<\/strong> Prescribing information for first-line medications for
\nsmoking cessation<\/caption>\n
Nicotine replacement therapy (NRT)
\nformulations<\/span><\/th>\n		Precautions<\/span><\/th>\nDosing by daily smoking level<\/span><\/th>\nTreatment duration<\/span><\/th>\nAdverse effects<\/span><\/th>\nAdvantages<\/span><\/th>\nDisadvantages<\/span><\/th>\nDaily cost, $1<\/a><\/sup><\/span><\/th>\n<\/tr>\n
Gum<\/strong>
\nNicorette2<\/a><\/sup>,
\n2 mg, 4 mg (regular, mint, orange)
\nGeneric3<\/a><\/sup>,
\n2 mg, 4 mg
\n<\/span><\/td>\n		Pregnancy; recent (<2 wk) myocardial infarction;
\nserious underlying arrhythmias; serious or worsening angina pectoris;
\ntemporomandibular joint disease<\/span><\/td>\n		(25 cigarettes: 2 mg
\n>=25 cigarettes: 4
\nmg<\/span><\/span>Week 1-6: 1 piece q 1-2 hr
\nWeek 7-9: 1 piece q 2-4 hr
\nWeek
\n10-12: 1 piece q 4-8 hr4<\/a><\/sup><\/td>\n		Up to 12 wk<\/span><\/td>\nMouth or jaw soreness; hiccups; dyspepsia;
\nhypersalivation; associated with incorrect chewing technique:
\nlightheadedness, nausea or vomiting, throat and mouth
\nirritation
\n<\/span><\/td>\n		May satisfy oral cravings; may delay weight gain;
\npatient can titrate therapy to manage withdrawal symptoms
\n<\/span><\/td>\n		Social acceptance of gum; difficult to use with
\ndentures; must use proper chewing technique to minimize adverse
\neffects
\n<\/span><\/td>\n		2 mg (9 pieces): 3.33 -5.16
\n4 mg (9 pieces): 3.78
\n-5.81<\/span><\/td>\n<\/tr>\n
Transdermal preparations<\/strong>
\nNicotrol patch5<\/a><\/sup>,
\n15 mg (16 hr)<\/span><\/td>\n		Pregnancy; recent (<2 wk) myocardial infarction;
\nserious underlying arrhythmias; serious or worsening angina pectoris;
\npatients with dermatologic conditions (eg, psoriasis, eczema, atopic
\ndermatitis)
\n<\/span><\/td>\n		>=10 cigarettes: 15 mg\/d for 6 wk
\n<10
\ncigarettes: not recommended
\n<\/span><\/td>\n		6 wk<\/span><\/td>\nLocal skin reactions (erythema, pruritus, burning);
\nheadache
\n<\/span><\/td>\n		One-step process; easy to use and conceal; fewer
\ncompliance issues
\n<\/span><\/td>\n		Patient cannot titrate doses; 16-hr release may lead to
\nearly morning (on waking) cravings; allergic reactions to adhesive may
\noccur
\n<\/span><\/td>\n		3.68<\/span><\/td>\n<\/tr>\n
Nicoderm CQ2<\/a><\/sup>,
\n21 mg, 14 mg, 7 mg (24 hr)
\n<\/span><\/td>\n		Same as for other transdermal systems
\n<\/span><\/td>\n		>10 cigarettes: 21 mg\/d for 6 wk; 14 mg\/d for 2 wk; 7
\nmg\/d for 2 wk
\n<=10 cigarettes: 14 mg\/d for 6 wk; 7 mg\/d for 2
\nwk<\/span><\/td>\n		8-10 wk<\/span><\/td>\nLocal skin reactions (erythema, pruritus, burning);
\nheadache; sleep disturbances (insomnia) or abnormal or vivid dreams
\n(associated with nocturnal nicotine absorption)<\/span><\/td>\n		Provides 24-hr steady-state levels, which may reduce
\nmorning cravings; easy to use and conceal; fewer compliance
\nissues
\n<\/span><\/td>\n		Patient cannot titrate doses; allergic reactions to
\nadhesive may occur
\n<\/span><\/td>\n		3.39<\/span><\/td>\n<\/tr>\n
Generic patch6<\/a><\/sup>
\n7<\/a><\/sup>,
\n21 mg, 14 mg, 7 mg (24 hr)
\n<\/span><\/td>\n		Same as for other transdermal systems
\n<\/span><\/td>\n		>=10 cigarettes: 21 mg\/d for 4 wk; 14 mg\/d for 2 wk;
\n7 mg\/d for 2 wk
\n<10 cigarettes: 14 mg\/d for 6 wk; 7 mg\/d for 2
\nwk<\/span><\/td>\n		8 wk<\/span><\/td>\nSame as for Nicoderm CQ<\/span><\/td>\nSame as for Nicoderm CQ
\n<\/span><\/td>\n		Same as for Nicoderm CQ
\n<\/span><\/td>\n		2.53-2.70<\/span><\/td>\n<\/tr>\n
Generic patch8<\/a><\/sup>,
\n22 mg, 11 mg (24 hr)
\n<\/span><\/td>\n		Same as for other transdermal systems
\n<\/span><\/td>\n		>15 cigarettes: 22 mg\/d for 6 wk
\n<=15
\ncigarettes: 11 mg\/d for 6 wk<\/span><\/td>\n		6 wk<\/span><\/td>\nSame as for Nicoderm CQ<\/span><\/td>\nSame as for Nicoderm CQ and one-step
\nproccess
\n<\/span><\/td>\n		Same as for Nicoderm CQ
\n<\/span><\/td>\n		3.11-3.50<\/span><\/td>\n<\/tr>\n
Nasal spray<\/strong>
\nNicotrol9<\/a><\/sup>
\nmetered spray (0.5 mg nicotine in 50-\u00b5L aqueous nicotine
\nsolution)<\/span><\/td>\n		Pregnancy; recent (<2 wk) myocardial infarction;
\nserious underlying arrhythmias; serious or worsening angina pectoris;
\nunderlying chronic nasal disorders (rhinitis, nasal polyps, sinusitis);
\nsevere reactive airway disease
\n<\/span><\/td>\n		1-2 doses\/hr (8-40 doses\/d); 1 dose = 2 sprays (1 in
\neach<\/em> nostril); each spray delivers 0.5 mg of nicotine to the nasal
\nmucosa<\/span><\/td>\n		3-6 mo<\/span><\/td>\nNasal and\/or throat irritation; rhinitis ; tearing;
\nsneezing; cough; headache
\n<\/span><\/td>\n		Patient can titrate therapy to rapidly manage withdrawal
\nsymptoms
\n<\/span><\/td>\n		Initial nasal or throat irritation may be bothersome;
\ndependence; wait 5 min before driving or operating heavy machinery (may
\ncause tearing or sneezing); avoid contact with skin (absorbed
\ntopically)<\/span><\/td>\n		3.40 for 8 doses<\/span><\/td>\n<\/tr>\n
Oral inhaler<\/strong>
\nNicotrol inhaler9<\/a><\/sup>,
\n10-mg cartridge delivers 4 mg inhaled nicotine vapor <\/span><\/td>\n		Pregnancy; recent (<2 wk) myocardial infarction;
\nserious underlying arrhythmias; serious or worsening angina pectoris;
\nunderlying reactive airway disease
\n<\/span><\/td>\n		6-16 cartridges\/d; individualized dosing<\/span><\/td>\nUp to 6 mo<\/span><\/td>\nMouth and\/or throat irritation; unpleasant taste; cough;
\nrhinitis; dyspepsia; hiccups; headache
\n<\/span><\/td>\n		Mimics hand-to-mouth ritual of smoking; patient can
\ntitrate therapy to manage withdrawal symptoms
\n<\/span><\/td>\n		Initial throat or mouth irritation may be bothersome;
\ncartridges should not be stored at temperatures <30\u00b0C (>86\u00b0F) or
\n<15\u00b0C (<59\u00b0F)
\n<\/span><\/td>\n		6.07 for 6 cartridges<\/span><\/td>\n<\/tr>\n
Bupropion hydrochloride SR<\/strong>
\nZyban10<\/a><\/sup>
\nsustained-release tablet<\/span><\/td>\n		Pregnancy; concomitant therapy with medications known to
\nlower the seizure threshold
\nContraindications: history of seizure
\ndisorder; history of bulimia or anorexia nervosa; MAO inhibitor therapy in
\nthe previous 14 days; concomitant therapy with other bupropion
\nproducts11<\/a><\/sup><\/span><\/td>\n		150 mg orally each morning for 3 days, then increase to
\n150 mg orally twice a day<\/span><\/td>\n		7-12 wk after quit date12<\/a><\/sup><\/span><\/td>\nInsomnia; dry mouth; nervousness or difficulty
\nconcentrating; rash; constipation; seizures risk 1\/1,000
\n(0.1%)
\n<\/span><\/td>\n		Ease of use; can be safely used in combination with NRT;
\nmay be beneficial in patients with coexisting depression
\n<\/span><\/td>\n		Seizure risk (rare); do not use in patients taking
\nmedications that can lower the seizure threshold
\n<\/span><\/td>\n		3.37<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

q = every;
\nMAO = monoamine oxidase.
\n<\/a>1<\/sup>Average wholesale price,
\n2001 Drug Topics Redbook.<\/em> Montvale, NJ: Medical Economics Company, Inc;
\n2001 Dec.
\n<\/a>2<\/sup>Nonprescription product distributed by
\nGlaxoSmithKline; web page for gum: http:\/\/www.nicorette.com\/<\/a>; web page for
\npatch: http:\/\/www.nicodermcq.com\/<\/a>. Note
\nthat trade names are given for information purposes only and are not to be
\nconstrued as endorsement by either the editors of this journal or the authors.<\/p>\n

<\/a>3<\/sup>Nonprescription product distributed by Watson
\nLaboratories.
\n<\/a>4<\/sup>Not to exceed 24 pieces a day.<\/p>\n

<\/a>5<\/sup>Nonprescription product distributed by Pharmacia
\nCorporation; web page: http:\/\/www.nicotrol.com\/<\/a>.
\n<\/a>6<\/sup>Nonprescription product (formerly Habitrol) distributed by
\nNovartis Consumer Health; web page: http:\/\/www.habitrol.com\/<\/a>.
\n<\/a>7<\/sup>Prescription product distributed by Schein Pharmaceuticals.<\/p>\n

<\/a>8<\/sup>Nonprescription product (formerly Prostep)
\ndistributed by Perrigo Company.
\n<\/a>9<\/sup>Prescription
\nproduct distributed by Pharmacia Corporation; web page: http:\/\/www.nicotrol.com\/<\/a>.
\n<\/a>10<\/sup>Prescription product distributed by GlaxoSmithKline; web
\npage: http:\/\/www.zyban.com\/<\/a>.
\n<\/a>11<\/sup>Such as Wellbutrin or Wellbutrin SR.
\n<\/a>12<\/sup>In some patients, maintenance treatment for as long as 6
\nmonths may be appropriate. <\/span><\/p>\n

<\/p>\n

 <\/p>\n\n\n\n
<\/p>\n<\/p>\n\n\n\n\n
\"\" Full Text of
\nthis Article<\/a> <\/span><\/td>\n<\/tr>\n
\"\" Email
\nthis article to a friend<\/a> <\/span><\/td>\n<\/tr>\n
\"\"
\neLetters: Submit a
\nresponse<\/a> to this article<\/strong>
\n<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/td>\n<\/tr>\n

<\/tbody>\n<\/table>\n

<\/p>\n

 <\/p>\n

 <\/p>\n

\n\n\n\n
HOME<\/span><\/a><\/td>\nHELP<\/span><\/a><\/td>\nFEEDBACK<\/span><\/a><\/td>\nSUBSCRIPTIONS<\/span><\/a><\/td>\nARCHIVE<\/span><\/a><\/td>\nSEARCH<\/span><\/a><\/td>\nTABLE OF
\nCONTENTS<\/span><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS   Full Text of this Article Email this article to a friend eLetters: Submit a response to this article       Table 1 Prescribing information for first-line medications for smoking cessation Nicotine replacement therapy (NRT) formulations Precautions Dosing by daily smoking level Treatment duration Adverse….<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":1166,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"class_list":["post-1170","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/pages\/1170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/comments?post=1170"}],"version-history":[{"count":1,"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/pages\/1170\/revisions"}],"predecessor-version":[{"id":1172,"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/pages\/1170\/revisions\/1172"}],"up":[{"embeddable":true,"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/pages\/1166"}],"wp:attachment":[{"href":"https:\/\/jacobimed.org\/old\/wp-json\/wp\/v2\/media?parent=1170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}